The Latest Cardiac and Vascular News
Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson PARIS–(BUSINESS WIRE)–Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today […]
– Early preclinical studies show peptide D6PV has the ability to activate the enzyme called Lipo-Protein Lipase (LPL), rapidly (within 1 -3 hours) reducing the number of triglycerides in the bloodstream – D6PV, an investigational drug, is being developed to address high triglyceride-induced acute pancreatitis (AP), a condition for which […]
WALTHAM, Mass., May 21, 2019 /PRNewswire/ — Corvidia Therapeutics Inc., a clinical stage biotechnology company, today announced the appointment of Dr. Preston Klassen, M.D., M.H.S. to its Board of Directors. Dr. Klassen is presently Executive Vice President, Head of Research and Development at Arena Pharmaceuticals, Inc. (Nasdaq: ARNA). A nephrologist with more than 20 years […]
WALTHAM, Mass.–(BUSINESS WIRE)– Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the appointment of Marc de Garidel as Chief Executive Officer. Mr. de Garidel succeeds Corvidia’s Michael Davidson, M.D., who will remain on the company’s executive team as Chief Scientific Officer. “As we transition from a clinical stage […]
